Detailed Data from Prevnar 13 CAPiTA Study Released

Detailed Data from Prevnar 13 CAPiTA Study Released
Detailed Data from Prevnar 13 CAPiTA Study Released

Pfizer has announced additional results from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) evaluating the efficacy of Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in preventing a first episode of vaccine-type community-acquired pneumonia (CAP) in adults aged ≥65 years. CAPiTA is the first trial to demonstrate a considerable reduction in vaccine-type pneumococcal and non-bacteremic/non-invasive vaccine-type pneumococcal CAP in adults.

RELATED: Immunization Resource Center

In this double-blind, randomized, placebo-controlled study of approximately 85,000 adults aged ≥65 years, there were 45.56% fewer first episodes of vaccine-type CAP among Prevenar 13-vaccinated patients compared to those receiving placebo (P=0.0006). For the secondary objectives, those receiving Prevenar 13 had 45% fewer first episodes of non-bacteremic/non-invasive vaccine-type CAP (P=0.0067) and 75% fewer first episodes of vaccine-type IPD (P=0.0005) compared to the placebo group. Data also showed that patients receiving Prevenar 13 had reductions in vaccine-type and non-bacteremic/non-invasive vaccine-type CAP, as well as vaccine-type IPD for up to four years post-vaccination.

Prevnar 13 is already indicated for the immunization of adults aged >50 years for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains; for the prevention of invasive disease caused by the 13 vaccine strains in children 6 weeks–17 years of age; and for the prevention of otitis media caused by 7 of the 13 strains in children 6 weeks–5 years of age.

For more information, call (800) 505-4426 or visit Prevnar13.com.

Loading links....